| 000 | 01885 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250517040841.0 | ||
| 264 | 0 | _c20160419 | |
| 008 | 201604s 0 0 eng d | ||
| 022 | _a1755-5949 | ||
| 024 | 7 |
_a10.1111/cns.12425 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChen, Sheng | |
| 245 | 0 | 0 |
_aA New VMAT-2 Inhibitor NBI-641449 in the Treatment of Huntington Disease. _h[electronic resource] |
| 260 |
_bCNS neuroscience & therapeutics _cAug 2015 |
||
| 300 |
_a662-71 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_a3,4-Dihydroxyphenylacetic Acid _xmetabolism |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 |
_aCorpus Striatum _xdrug effects |
| 650 | 0 | 4 | _aDNA-Binding Proteins |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 |
_aDopamine _xmetabolism |
| 650 | 0 | 4 |
_aDopamine and cAMP-Regulated Phosphoprotein 32 _xmetabolism |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHomovanillic Acid _xmetabolism |
| 650 | 0 | 4 |
_aHuntington Disease _xdrug therapy |
| 650 | 0 | 4 | _aMice, Transgenic |
| 650 | 0 | 4 |
_aMotor Activity _xdrug effects |
| 650 | 0 | 4 |
_aNerve Tissue Proteins _xmetabolism |
| 650 | 0 | 4 |
_aNeurons _xdrug effects |
| 650 | 0 | 4 |
_aNeuroprotective Agents _xpharmacology |
| 650 | 0 | 4 |
_aNuclear Proteins _xmetabolism |
| 650 | 0 | 4 |
_aSerotonin Plasma Membrane Transport Proteins _xmetabolism |
| 650 | 0 | 4 |
_aTyrosine 3-Monooxygenase _xmetabolism |
| 650 | 0 | 4 |
_aVesicular Monoamine Transport Proteins _xantagonists & inhibitors |
| 700 | 1 | _aZhang, Xiao-Jie | |
| 700 | 1 | _aXie, Wen-Jie | |
| 700 | 1 | _aQiu, Hong-Yan | |
| 700 | 1 | _aLiu, Hui | |
| 700 | 1 | _aLe, Wei-Dong | |
| 773 | 0 |
_tCNS neuroscience & therapeutics _gvol. 21 _gno. 8 _gp. 662-71 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/cns.12425 _zAvailable from publisher's website |
| 999 |
_c25028116 _d25028116 |
||